Shared on 01 Nov 25
Fair value Decreased 0.60%Narrative Update: Zoetis Analyst Price Target Adjustment Analysts have modestly decreased their price target for Zoetis from $165 to $158, citing a more cautious outlook ahead of upcoming results. Analyst Commentary Analyst perspectives on Zoetis highlight both optimism regarding the company’s long-term fundamentals as well as heightened caution leading into upcoming earnings releases.
Shared on 18 Oct 25
Fair value Decreased 0.21%Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $189.22 to $188.83, citing modest revisions to revenue growth estimates. They also noted a marginal increase in expected profit margins.
Shared on 04 Oct 25
Fair value Decreased 0.56%Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $190.29 to $189.22, citing marginally softer revenue growth and profit margin expectations. What's in the News Zoetis received conditional FDA approval for Dectomax-CA1, the first and only injectable for preventing and treating infestations caused by New World screwworm larvae in cattle.
Shared on 07 May 25
Fair value Decreased 3.03%Companion Animal And Livestock Demand Will Unlock Future Opportunities
Shared on 30 Apr 25
Fair value Decreased 1.42%Companion Animal And OA Portfolios Will Unlock Market Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 0.32%Companion Animal And OA Portfolios Will Unlock Market Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 0.94%Companion Animal And OA Portfolios Will Unlock Market Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.055%Companion Animal And OA Portfolios Will Unlock Market Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 0.39%Companion Animal And OA Portfolios Will Unlock Market Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Companion Animal And OA Portfolios Will Unlock Market Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Companion Animal And OA Portfolios Will Unlock Market Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 3.81%Companion Animal And OA Portfolios Will Unlock Market Potential
AnalystConsensusTarget has decreased revenue growth from 5.9% to 4.6%.